APA (7th ed.) Citation

C, E., H, R., & J, K. (2025). Authors' reply: Apixaban, edoxaban and rivaroxaban, but not dabigatran, are associated with higher mortality compared to vitamin K antagonists. Journal of internal medicine, 297(1), 119. https://doi.org/10.1111/joim.20045

Chicago Style (17th ed.) Citation

C, Engelbertz, Reinecke H, and Köppe J. "Authors' Reply: Apixaban, Edoxaban and Rivaroxaban, but Not Dabigatran, Are Associated with Higher Mortality Compared to Vitamin K Antagonists." Journal of Internal Medicine 297, no. 1 (2025): 119. https://doi.org/10.1111/joim.20045.

MLA (9th ed.) Citation

C, Engelbertz, et al. "Authors' Reply: Apixaban, Edoxaban and Rivaroxaban, but Not Dabigatran, Are Associated with Higher Mortality Compared to Vitamin K Antagonists." Journal of Internal Medicine, vol. 297, no. 1, 2025, p. 119, https://doi.org/10.1111/joim.20045.